Cullinan Therapeutics, Inc. — Form 8-K
Filed September 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Cullinan Therapeutics and partners Taiho Oncology/Taiho Pharmaceutical announced that zipalertinib plus chemotherapy met its primary endpoint in the Phase 3 REZILIENT3 trial for first-line EGFR exon 20 insertion-positive NSCLC, demonstrating a statistically significant median PFS improvement of 6.0 months (14.5 vs. 8.5 months; HR=0.50; P=0.00015) in 279 enrolled patients. At interim OS analysis (30% maturity), the hazard ratio was 0.72 (95% CI 0.42–1.23); objective response rate was 65% vs. 40.3% for chemotherapy alone.
Why this rating
Phase 3 win for co-developed asset with meaningful efficacy in addressable niche (EGFR ex20ins ~12% of EGFR+ NSCLC). Regulatory approval potential; modest probability of material royalty/milestone revenue for $442M company, but partnership structure limits upside capture.
See more from September 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.